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Summary
The rise of antibiotic resistance threatens modern medicine; to combat it new diagnos-
tic methods are required. Sequencing the whole genome of a pathogen offers the potential
to accurately determine which antibiotics will be effective to treat a patient. A key limi-
tation of this approach is that it cannot classify rare or previously unseen mutations. Here
we demonstrate that alchemical free energy methods, a well-established class of methods
from computational chemistry, can successfully predict whether mutations in Staphylococ-
cus aureus dihydrofolate reductase confer resistance to trimethoprim. We also show that
the method is quantitively accurate by calculating how much the most common resistance-
conferring mutation, F99Y, reduces the binding free energy of trimethoprim and compar-
ing predicted and experimentally-measured minimum inhibitory concentrations for seven
different mutations. Finally, by considering up to 32 free energy calculations for each mu-
tation, we estimate its specificity and sensitivity.
INTRODUCTION
Resistance of bacteria to the antibiotics used to treat them is a substantial and growing global
threat to human health (Davies, 2013; World Economic Forum, 2013). Measures to counter
the emergence of antibiotic resistance are restricted by the limitations of conventional diagnos-
tic microbiology. This predominantly still relies on culture-based, phenotypic identification of
bacteria followed by growth in the presence of different antibiotic concentrations to detect re-
sistance. The process is labour intensive, takes days or even weeks depending on the growth
rate of the organism in question, is expensive and open to subjective interpretation. Genetic ap-
proaches, particularly those based on sequencing the entire genome of a pathogen (Didelot et al.,
2012; Köser et al., 2014), have the potential to be faster and cheaper. Inferring the phenotype
of an infecting pathogen from whole-genome sequence data by considering known resistance
genes or mutations has already been shown to be reasonably accurate for a range of pathogens
(Gordon et al., 2014; Walker et al., 2015; Pankhurst et al., 2016; Bradley et al., 2015) and has
recently been implemented in the U.K. for the routine diagnosis of M. tuberculosis infections
2
(Walker et al., 2017). New mutations, however, continually arise and a genetics-based clinical
microbiology service therefore also needs to be able to predict the effect of novel mutations. In
this paper we demonstrate that molecular-based computational chemistry methods can predict
whether individual protein mutations confer resistance to an antibiotic.
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Figure 1: Seven mutations in S. aureus dihydrofolate reductase (DHFR) were chosen from a
whole genome sequencing study of clinical isolates (Gordon et al., 2014) to test our approach
(A) Trimethoprim (TMP) competes with the natural substrate, dihydrofolic acid (DHA), for
binding to DHFR, thereby inhibiting the action of this essential protein. (B) A structure of
chromosomal S. aureus DHFR (dfrB) bound with TMP and NADPH, as resolved by X-ray
crystallography (Oefner et al., 2009). Three of the mutations, colored red (F99Y, F99Y/L21V
& L41F), were previously shown to confer resistance to TMP, whilst the remaining four, colored
blue (F123L, A135T, V76A, I83V), remained susceptible to the action of the antibiotic (Gordon
et al., 2014). This classification was confirmed by independent measurement of TMP minimum
inhibitory concentrations for each mutant (Table S1 & S2). These colors are used throughout.
As proof of principle we have investigated the effect of mutations to Staphylococcus au-
reus dihydrofolate reductase (DHFR) on the binding of the antibiotic trimethoprim (TMP, Fig.
1A). S. aureus is a clinically important gram-positive pathogen and has been the focus of much
research due to the development of methicillin- and vancomycin-resistant strains, known as
MRSA and VRSA, respectively. TMP, usually administered as co-trimoxazole (trimethoprim-
sulfamethoxazole), has a long history of treating S. aureus infections (Tong et al., 2015) in-
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cluding common skin and soft tissue infections caused by MRSA strains (Nurjadi et al., 2014).
TMP competes with the natural substrate, dihydrofolic acid (DHA, Fig. 1A), for binding to
DHFR, thereby preventing DHFR catalyzing the conversion of DHA to tetrahydrofolic acid.
Since tetrahydrofolate is essential for the biosynthesis of thymidylate, purine nucleotides, and
some amino acids, arresting the production of DHA inhibits bacterial growth. Resistance to
TMP in S. aureus can either arise from mutations in the chromosomal gene dfrB, or from the
introduction of other naturally-resistant genes (dfrA, dfrG and dfrK) via plasmids (Lowy, 2003;
Nurjadi et al., 2014). Here we focus on seven mutations in the dfrB chromosomal gene. We have
chosen this gene for five reasons: (i) a series of resistance-conferring and no-effect mutations
have been identified via whole-genome sequencing of isolates from patient infections (Gordon
et al., 2014), as well as by more traditional methods, (ii) the most common resistance-conferring
mutation is a very small chemical change (Phe! Tyr) and this is therefore a challenging test
for any predictive approach, (iii) DHFR is a small, soluble protein that has been well-studied,
(iv) several experimental structures exist of S. aureus DHFR bound to TMP (Fig. 1B) (Dale
et al., 1997; Oefner et al., 2009; Heaslet et al., 2009) and (v) there is published quantitative
biophysical data on how the most common resistant-conferring mutation in S. aureus affects
the binding of TMP to DHFR (Pires et al., 2015; Oefner et al., 2009; Dale et al., 1997; Frey
et al., 2010, 2012). Since this is a classification problem we emphasise the importance of hav-
ing negative controls (that is, mutations that are known to have no effect). This underscores the
vital importance of clinical whole genome sequencing studies as these naturally identify large
numbers of such mutations.
Our hypothesis is that chromosomal mutations in an open reading frame will confer resis-
tance if the mutation causes the antibiotic molecule to bind less well to the encoded protein,
whilst, crucially, not significantly affecting how well the natural substrate binds. This is only
one of several mechanisms by which bacteria can evolve resistance to antibiotics (Blair et al.,
2014). Other mechanisms include the introduction, by horizontal gene transfer, of genes en-
coding either proteins that degrade antibiotics, for example b -lactamases which are common
in gram-negative bacteria, or, as mentioned above, naturally resistant versions of chromosomal
proteins. The over-expression of efflux pumps can reduce the concentration of the antibiotic
within the bacterium to below effective levels or the cell well can simply be impenetrable to
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most antibiotics, the most notable example of this beingM. tuberculosis.
The binding free energy (DG) is the thermodynamic quantity that captures how strongly a
small molecule, like an antibiotic, is bound to a protein. Our hypothesis therefore distills down
to calculating how a specific mutation affects the binding free energies, relative to the wildtype
(wt), of both TMP and DHA
DDGTMP = DGmutantTMP  DGwtTMP
DDGDHA = DGmutantDHA  DGwtDHA
Whilst it would be trivial for a mutation to disrupt the binding of the antibiotic (i.e. DGmutantTMP >
DGwtTMP and so DDGTMP > 0), it is difficult for a mutation to simultaneously not disrupt the bind-
ing of the natural substrate (i.e. DGmutantDHA ⇠ DGwtDHA leading to DDGDHA ⇠ 0). For a mutation to
give rise to a viable strain of S. aureus that is resistant to TMP a first estimate of a binding free-
energy criterion is therefore is that DDGTMP > 0 and DDGDHA ⇠ 0. By making some simple
assumptions and applying kinetic theory, we will relate these changes in binding free energies to
the minimum inhibitory concentrations (MICs) of the antibiotics. This is the quantity measured
by clinical microbiology laboratories, and we are able, through MICs distributions published
by the European Committee on Antimicrobial Susceptibility Testing (EUCAST), derive more
sophisticated criteria based on clinical data.
To calculate how the binding free energy of either the antibiotic or the natural substrate
changes upon introduction of the mutation we will apply Hamiltonian-exchange thermody-
namic integration, an alchemical free energy method (Fowler et al., 2005; Gilson and Zhou,
2007; Fowler et al., 2007; Michel et al., 2010; Chodera et al., 2011; Gapsys et al., 2015a; Perez
et al., 2016; Abel et al., 2017). Alchemical free energy methods are derived from classical sta-
tistical mechanics and calculate the cost of perturbing a chemical moiety, such as an amino acid
sidechain, into another using a series of classical molecular dynamics (MD) simulations; hence
they are dubbed ‘alchemical’. There are no free parameters, and so in theory are exact, although
in practice there are always likely to be errors due to imperfections in the parametrisation of the
molecules and the incomplete exploration of the dynamical phase space of the system during
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the simulations. We will not consider here other methods of calculating or estimating binding
free energies, such as computational docking, ‘endpoint’ methods or protein design or stability
algorithms, since they are unlikely, in our opinion, to capture the subtlety of the molecular per-
turbations. Since each free energy calculated by an alchemical free energy method requires a
number of molecular dynamics simulations, this approach potentially requires large amounts of
computational resource; however, given the continued increase in computing speeds this class
of methods is coming of age and is beginning to find application (Wang et al., 2015; Samsudin
et al., 2016; Gapsys et al., 2016; Lenselink et al., 2016).
Traditionally, a single calculation would be run for each perturbation (here a protein mu-
tation) and the error in the free energy estimated by, e.g. dividing the simulation trajectories
into ‘independent’ sections by calculating a correlation time. Since this is a clinically impor-
tant problem where the accuracy of the classification, and potentially also minimising the time
taken to return a prediction, are essential, we shall instead run a large ensemble of relatively-
short thermodynamic integration calculations for each mutation, simplifying the estimation of
confidence intervals, as well as, subject to having sufficient computational resource, potentially
reducing the time to solution. In the second half of the paper we will estimate the sensitivity
and specificity of our method.
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RESULTS
Clinically a mutation is described as resistant if the minimum concentration of an antibiotic
that inhibits the growth of the bacteria is greater than a reference concentration. According to
the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2016), S. aureus
is defined as not susceptible to TMP (i.e. resistant) if its minimum inhibitory concentration
(MIC) is   4 mg/l. Since TMP is a competitive inhibitor of DHFR and, assuming Michaelis-
Menten enzyme kinetics (Price et al., 2009), then as shown in the Supplemental Information, if
we assume that the mutation only affects the dissociation equilibrium constant of the antibiotic
(Ki) we can derive a simple binding free-energy based resistance criterion,
DDGTMP   0.8 kcal/mol. (R1)
This assumes that the enzyme rate constant and the concentrations of the enzyme and the sub-
strate are all unaffected by the mutation. Alternatively, if we allow the protein mutation to affect
the dissociation constants of both the inhibitor and the natural substrate, then we find a second
resistance criterion,
DDGTMP DDGDHA   0.8 kcal/mol. (R2)
This is a more nuanced view of how resistance can arise: resistance is conferred if a mutation
increases how well the natural substrate binds (DDGDHA < 0), as well as decreasing how well
the antibiotic binds (DDGTMP > 0). It is likely, however, that large changes in the magnitude of
DDGDHA will affect the action and turnover rate of the enzyme and so, in practice, there will be
a limit on how much a mutation can affect the binding of the natural substrate. Applying either
of the above criteria generates a prediction of whether a mutation confers resistance or not and
one of the aims of this paper is to assess if criterion R2 is more accurate and precise than R1. For
either resistance criterion to classify a mutation as conferring resistance (or having no effect) the
relevant free energy in R1 or R2 must be lie demonstrably one side of the 0.8 kcal/mol threshold
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or the other; if the confidence limits bracket the threshold, then either criterion must return a
classification of ‘unknown’. This is a small departure from most culture-based microbiology
tests which simply return a binary ‘resistant’ or ‘susceptible’ classification.
We chose a series of mutations in the chromosomal gene dhfB identified by whole-genome
sequencing of S. aureus clinical infections from two hospitals in the UK (Gordon et al., 2014).
As expected, by far the most common naturally occurring TMP resistance-conferring muta-
tion in S. aureus DHFR was F99Y (Gordon et al., 2014; Dale et al., 1997). Several studies
have shown that this common mutation reduces the binding free energy of TMP to S. aureus
DHFR by 2.0 ± 0.2 kcal/mol (Dale et al., 1997; Oefner et al., 2009; Frey et al., 2010, 2012;
Pires et al., 2015), equivalent to a 24 fold increase in the dissociation constant, Ki. This is a
large effect given the mutation only replaces a hydrogen by a hydroxyl. Two further resistance-
conferring mutations were chosen: L41F, which has also been previously observed (Vickers
et al., 2009), and the double mutation F99Y/L21V, which has not – the related triple mutation
F99Y/L21V/N60I was, however, identified as resistant 20 years ago (Dale et al., 1997). Mu-
tating two residues simultaneously is likely to lead to convergence issues, and we therefore de-
composed the double F99Y/L21V mutation into two separate mutations, F99Y and Y99L21V,
summing the free energies to obtain the result for the double mutation (Klimovich et al., 2015).
Although it has not yet been observed in isolation, we also calculated the effect of the iso-
lated L21V mutation, allowing us to test the additivity of these mutations. Both the L41F and
F99Y/L21V mutations are rare, only being observed once each among nearly 1,000 UK clin-
ical isolates (Gordon et al., 2014). Any classification method must be able to distinguish true
positives from true negatives, and therefore we also studied the effect of four mutations in S.
aureus DHFR that were each detected multiple times in the isolate collection and had no effect
on the action of TMP based on the results of conventional drug susceptibility testing. These
were F123L, A135T, V76A and I83V (Fig. 1B) and are negative controls.
To confirm the phenotype of these seven mutations and to provide a consistent quantitative
dataset, a subset of the clinical isolates that were sequenced as part of the previous study (Gor-
don et al., 2014) were retrieved and re-tested as described in the Methods. The TMPMICs were
determined for each patient isolate (Table S1); up to five independent measurements were ob-
tained, depending on how many clinical isolates of that mutation existed. The values obtained
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agree well with both MIC values recorded by Public Health England during routine testing (Ta-
ble S2) and those previously reported in the literature (Pires et al., 2015; Dale et al., 1997; Frey
et al., 2010, 2012; Vickers et al., 2009).
Alchemical free energy calculations accurately predict which mutations
confer resistance
Using our chosen alchemical free method (see Methods) we calculated how the free energy of
binding of both TMP (DDGTMP) and DHA (DDGDHA) varies upon introducing each of the seven
clinically-observed mutations. Thirty two values of DDGTMP and DDGDHA were calculated for
each mutation, making 512 DDG values in total. Since each pair of (DDGTMP,DDGDHA) values
necessitated the calculation of 13 different DG values (Fig. S5), that makes 3,328 separate free
energies. Since they originate from separate sets of simulations, each DDG value is assumed
to be independent, and therefore it is straightforward to examine how the values of DDGTMP
and DDGDHA converge as the number of calculations, n, increases (Fig. 2). As expected, the
uncertainty in the free energy is a maximum around n = 3 and then falls as the number of
calculations is increased. The mutations with the largest confidence intervals are also those
which perturb the largest number of atoms (F99Y/L21V, L41F and F123L).
The above analysis assumes that each DDG calculation is itself converged; the standard way
to test this would be to compare the forward and reverse cumulative averages of each DDG value
(Yang et al., 2004; Klimovich et al., 2015). This is not possible here due to the large numbers
of DDG values; instead we demonstrate that increasing or decreasing the proportion of each
simulation that is discarded does not significantly alter either the calculated numerical values,
or the resulting classification (Fig. S1 & S2).
Whilst our predicted value of DDGTMP for the common F99Y mutation (1.5± 0.2 kcal/mol)
Fig. 3A, Table S3) does not agree within error with the mean value (2.0 ± 0.2 kcal/mol) of
several previously published isothermal titration calorimetry (ITC) measurements (Pires et al.,
2015; Oefner et al., 2009; Dale et al., 1997; Frey et al., 2010, 2012), there is considerable over-
lap between the predicted and experimental values. Furthermore, all three known resistance-
conferring mutations (F99Y, F99Y/L21V and L41F) are predicted to reduce how well TMP
9
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binds to DHFR (DDGTMP> 0, Fig. 3B, Table S3). Since these mutations were predicted to,
on average, increase DDGTMP by significantly more than 0.8 kcal/mol, they are classified as
conferring resistance to TMP by criterion R1. Of the four negative control mutations, three are
predicted to have ‘no effect’ on the action of TMP, although the 0.8 kcal/mol threshold is just
outside the confidence limits for the F123L mutation. Since the 95% confidence limits for the
remaining I83V mutation cross the threshold, this mutation is classified as having an ‘unknown’
phenotype.
But how do the mutations affect the binding of the natural substrate, DHA? In contrast to
the binding of TMP, all the mutations, with the exception of L41F and I83V, are predicted to
either have no effect on the binding of DHA, or to increase how strongly DHA binds to DHFR
(Fig. 3C, Table S4). By considering the mean values for all four no-effect mutants, we find they
are not predicted to change the magnitude of DDGDHA by more than 0.5 kcal/mol, in line with
our expectation that DDGDHA⇠ 0.
Plotting the mean values of DDGDHA against DDGTMP (Fig. 4) allows us to classify the
seven mutations using the second resistance criterion (R2). This condition predicts that all
three known resistance-conferring mutations confer resistance to TMP, whilst of the four neg-
ative controls, three (V76A, A135T and I83V) are correctly predicted to have no effect on the
action of TMP. Since the confidence limits of the remaining F123L mutation straddle the 0.8
kcal/mol threshold, it is predicted to have an ‘unknown’ effect. If the natural substrate binds
more strongly to the enzyme (DDGDHA< 0), one could hypothesise that this should improve
the turnover rate, if binding is the rate-limiting step. We speculate that L41F and I83V (espe-
cially the former) induce a fitness cost, since they reduce how well DHA binds to DHFR, whilst
V76A, F99Y and particularly F99Y/L21V, bring a fitness benefit, with the others have no effect
on the fitness of the enzyme. Since the free energies for the L21V and Y99L21V mutations
(Table S3 & S4) are identical, to within error, we conclude that the effects of the F99Y and
L21V mutations on the binding of TMP or DHA in the double F99Y/L21V mutant are additive
.
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Figure 3: Thermodynamic integration correctly calculates how much the F99Y mutation re-
duces the TMP binding free energy and the R1 resistance criterion correctly classifies 6 of
the 7 clinical mutations. (A) Whilst the predicted change in the binding free energy of TMP
(DDGTMP) due to the F99Y mutation does not agree with previously published experimental
data, the difference is small. (B) Applying resistance criterion R1 correctly classifies the F99Y,
F99Y/L21V and L41F mutations as conferring resistance to TMP. The mutation L21V is also
predicted to confer resistance. Of the four mutations known to have no effect on the action of
TMP, F123L, A135T and V76A are correctly classified as not conferring resistance and I83V is
classified as having an unknown effect. The fold change in the dissociation equilibrium constant
(Ki) is also shown. Each value of DDG is the mean of 32 independent calculations (Tables S3,
S4), and the bars represent 95% confidence limits, using the appropriate t-statistic. The initial
20% of each simulation has been discarded to avoid equilibration effects. Discarding 10% or
50% of the data does not alter these conclusions (Fig. S1 & S2 ). (C) The same calculations
were repeated, but with dihydrofolic acid (DHA) bound. With the exception of L41F and I83V,
no mutation decreases how well DHA binds to DHFR, to within error.
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Figure 4: The R2 resistance criterion correctly predicts the effect of six of the seven mutations,
with F123L being classified as having an unknown effect. (A) Plots of how each mutation is
predicted to affect the binding of DHA against TMP (i.e. Fig. 3B v. C) for each of the 32
independent pairs of calculations. The region defined by the R2 resistance criterion is shaded
grey. (B) Plotting the mean values with 95% confidence intervals demonstrates that the R2
resistance criterion correctly classifies all bar the F123 mutation which is predicted to have an
unknown effect. The variation with n is shown in Fig. S3. All mutations are colored according
to the same scheme as Fig. 1.
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Predicting minimum inhibitory concentrations.
A stronger test of our approach is to compare against quantitative, rather than qualitative, data
for all the mutations tested, rather than just F99Y. In the absence of quantitative binding data
for the other mutations (as measured by e.g. ITC), we can instead predict the MIC for each
mutation using Equation S2 and then compare it to the experimentally observed mean MICs
(Table S1). As described in the Methods, the TMP MICs were measured by bioMérieux E-
test. These have a roughly-doubling ladder of antibiotic concentrations going from 0.002 to 32
mg/L, a range of 16,000 fold. At first glance, there is a good correlation between the predicted
and observed MICs (Fig. 5). This is, however, not a thorough test since (i) the experimental
values have an upper limit of > 32 mg/ml and so we cannot distinguish between the different
resistance-conferring mutations and (ii) there are no mutations that confer an intermediate level
of resistance. Despite this, five of the seven predicted MICs can be said to be in ‘essential
agreement’, since they are within a single doubling dilution (within the 2⇥ lines) of the refer-
ence method value (ISO, 2007) and, overall, it is promising that it appears possible to predict
MICs to within a factor of 2-4.
We conclude that alchemical free energy methods are not only able to distinguish resistance-
conferring mutations from susceptible mutations but also, by comparing to ITC data and MIC
data, can make quantitatively accurate predictions, although more work is required before it
will be possible to confirm that one can formally relate DDG values to MICs. This proof of
principle also study suggests that a good level of confidence in the phenotype of a mutation can
be obtained by only predicting the effect on the binding of the antibiotic (i.e. criterion R1), in
this case trimethoprim.
Classifying mutations using an alchemical free energy method is sensitive
and specific.
Given predictions made by this type of approach could, one day, be used to drive clinical deci-
sion making, it is essential to establish the sensitivity and specificity of the method. First, let us
assume that our sets of 32 pairs of DDGTMP and DDGDHA values per mutation are representative.
The classification performance of the method can then be modelled by repeatedly drawing (with
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Figure 5: Our predicted values of the minimum inhibitory concentration (MIC) of trimetho-
prim correlate moderately well with the experimentally measured MICs. The predicted values
are inferred from how the mutation alters the relative binding of trimethoprim (TMP) and dihy-
drofolic acid using Equation S4. Note that since the bioMérieux E-test does not measure above
32 mg/l, we have likewise cut off our predicted values at > 32 mg/l. The predicted mean MIC
for the F99YL21V mutation is very large (⇠ 2,400 mg/l) and therefore cannot be plotted in this
range. Clinically, a S. aureus DHFR mutation is classified as resistant if the TMPMIC  4 mg/l
(EUCAST, 2016); this region is shaded light grey. To aid interpretation, lines corresponding
to a perfect correlation, and within factors of 2⇥ and 4⇥ are drawn. Since our calculations
only yield a fold increase in the MIC, all the predicted MIC values are assumed to be relative
to a wildtype (geometric mean) MIC of 1.1 mg/l (EUCAST, 2016). The mutations are colored
according to the same scheme as Fig. 1.
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replacement) samples containing n values of DDGTMP and n values of DDGDHA and applying
either resistance criterion to produce a classification. We repeated this bootstrapping approach
10,000 times at each value of 2 n 32 and a summary of the results at five distinct values of
n 2 {3,5,10,16,32} is shown in Fig. 6 (see also Fig. S4). Interestingly, even at small values of
n, the method is unlikely to return an incorrect categorical prediction – the highest false cate-
gorisation rate occurs when applying the R1 resistance criterion to the I83V mutation at n= 3,
and even then our analysis suggests the method would have incorrectly classified this mutation
as conferring resistance only 2.5 % of the time with an ‘unknown’ result being returned in 91%
of cases. We conclude that the method is robust in the sense that once n is large enough for it to
return a definite categorisation it is highly likely to be correct.
The performance of a binary classification process is usually assessed by considering the
true positive and true negative rates of detection, often referred to as the sensitivity and speci-
ficity, respectively. These are given in Table 1. Since our approach gives a ternary classification
(‘unknown’ in addition to ‘resistant’ and ‘susceptible’), there are two ways one can define the
sensitivity and specificity. The difference rises from whether one includes the uncharacterised
cases in the numbers of false positives and false negatives, or whether these cases can be ex-
cluded, since the method has (correctly) not attempted a definitive classification. If we first
consider the former, more conservative definition, then the sensitivities / specificities are rela-
tively low at small values of n and increase with n, achieving 99.7 / 61.3% for the R1 resistance
criterion and 78.6 / 72.8% for the R2 criterion at n= 10 before reaching 100.0 / 77.9% and 84.0
/ 91.0% at n= 32, respectively (Table 1). However, the proportion of uncharacterised cases fall
dramatically from 37% (55%) for the first (second) resistance criterion at n= 3, to 11% (13%)
at n = 32. If all these cases are excluded then all the sensitivities and specificities are   98%,
suggesting that (i) the increase in the conservative estimates of the sensitivities and specificities
is entirely driven by the decrease in the proportion of uncharacterised cases and (ii) our previ-
ous observation that the method rarely incorrectly classifies a mutation is correct. We conclude
that the main effect of increasing the number of free energy calculations used in a prediction
is increasing the likelihood that a definite classification will be made. We cannot, though, con-
clude which resistance criterion is ‘better’ since both the R1 and R2 resistance criteria struggle
to classify two mutations each (F123L & I83V and F123L & L41F, respectively), even at high
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values of n. Difficulties in classifying a mutation are due to a combination of where it hap-
pens to fall relative to the two free energy thresholds on the (DDGTMP,DDGDHA) plane (Fig.
4, S3) and the variability between individual free energy calculations, which is related to the
magnitude of the perturbation. The performance of either criteria therefore critically depends
on which mutations have been selected to make up a test-set and, since we have only studied
seven mutations, we cannot yet conclude which is preferable. Allowing a mutation to affect the
binding of the natural substrate as well as the antibiotic is more elegant and hence one would
expect the R2 resistance criterion to be more accurate, but it also requires 138 ⇥ the number of
free energy calculations (Fig. S5).
One final possibility is to use the classifications from both criteria to make an ensemble
prediction. The cases where both resistance criteria agree are trivial; the key question is how to
classify mixed classifications e.g. RU. Here we assume that a definitive classification (‘resistant’
or ‘susceptible’) will overrule any ‘unknown’ classification and ‘resistant’ will overrule ‘sus-
ceptible’. Hence if the results of applying the R1 and R2 resistance criteria can be represented
as two letters, we shall define our ensemble rules for predicting resistance, susceptibility or un-
known phenotypes as [RR,RU,UR,RS,SR], [SS,SU,US] and [UU], respectively. This ensemble
method improves the classification performance, as measured by sensitivities and specificities
(Table 1), for these seven mutations at least. It is, however, slightly unsatisfying since it weak-
ens the link between the effect of the mutation on how well the antibiotic binds to the protein
and the effectiveness of the drug.
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(a) Resistance criterion R1. DDGTMP   0.8 kcal/mol
all excluding uncharacterised
n sensitivity specificity sensitivity specificity uncharacterised
3 70.3 % 53.8 % 100.0 % 98.5 % 37.5 %
5 90.8 % 57.9 % 100.0 % 99.1 % 25.4 %
10 99.7 % 61.3 % 100.0 % 99.7 % 19.4 %
16 100.0 % 66.6 % 100.0 % 99.9 % 16.7 %
32 100.0 % 77.9 % 100.0 % 100.0 % 11.1 %
(b) Resistance criterion R2. DDGTMP+DDGDHA   0.8 kcal/mol
all excluding uncharacterised
n sensitivity specificity sensitivity specificity uncharacterised
3 60.4 % 29.4 % 99.6 % 99.2 % 54.9 %
5 75.1 % 46.7 % 99.8 % 99.9 % 39.1 %
10 78.6 % 72.8 % 99.9 % 100.0 % 24.2 %
16 80.3 % 82.7 % 100.0 % 100.0 % 18.5 %
32 84.0 % 91.0 % 100.0 % 100.0 % 12.5 %
(c) Consensus. Taking (R1,R2) then: R=(RR,RU,UR), S=(SS,SU,US), U=UU
all excluding uncharacterised
n sensitivity specificity sensitivity specificity uncharacterised
3 82.3 % 59.3 % 99.8 % 98.4 % 28.6 %
5 96.8 % 68.0 % 99.9 % 99.2 % 17.3 %
10 100.0 % 79.5 % 100.0 % 99.8 % 10.2 %
16 100.0 % 86.8 % 100.0 % 99.9 % 6.6 %
32 100.0 % 94.3 % 100.0 % 100.0 % 2.8 %
Table 1: The expected proportion of classifications which would be returned with an ‘unknown’
phenotype decreases as the number of calculations, n, increases. The resulting sensitivities and
specificities also increase with n. Two sets are given; the latter excludes all classifications
with an unknown phenotype. All sensitivities and specificities are estimated by creating 10,000
samples of n values of DDGTMP and n values of DDGDHA by drawing-with-replacement from the
larger set of 32 calculations. Results are given for the (a) R1 and (b) R2 resistance criteria. (c)
Applying a consensus where any definitive ‘resistance’ or ‘susceptible’ classification overrules
any ‘unknown’ classification is optimal.
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DISCUSSION
We have shown that alchemical free energy methods can predict whether mutations in S. aureus
DHFR confer resistance or not to the antibiotic trimethoprim. This paves the way for the intro-
duction of such structural-based predictivemethods into a genetics-based clinical microbiology
service (Didelot et al., 2012; Köser et al., 2014) – allowing novel or insufficiently-characterised
mutations to be assessed, thereby mitigating one of the key weaknesses of genetics-based clini-
cal microbiology. The potential benefits of transitioning from laboratory- to genetics-based mi-
crobiology in the clinical setting are large: a reduction in the time for drug susceptibility testing
(especially for slow-growing pathogens such as Mycobacterium tuberculosis), automatic epi-
demiological monitoring of the dispersal of specific resistance mechanisms and ever-decreasing
cost. The switch to a genetics-based clinical microbiology will ultimately lead to increased pre-
cision in antibiotic prescribing and reduced selection for antibiotic resistance. The clinical tran-
sition has just begun: in early 2017 Public Health England adopted whole-genome sequencing
for routine drug susceptibility testing for M. tuberculosis infections (Walker et al., 2017) and
other countries look likely to follow suit.
Establishing the accuracy and reproducibility of any predictive method is essential, espe-
cially if it could ultimately drive decisions in a clinical setting. We emphasise the vital im-
portance of (i) having negative controls, which here was enabled by a previous clinical whole-
genome sequencing (WGS) study (Gordon et al., 2014), (ii) running multiple repeats, which
has the additional benefit of simplifying the estimation of errors (Coveney and Wan, 2016), and
(iii) systematically assessing the sensitivity and specificity of any method.
Ultimately, for predictions made by a computational method such as ours to form part of
an antimicrobial diagnostic workflow, it must satisfy the same standards as any new lab-based
diagnostic method (ISO, 2007; U.S. Department of Health and Human Services Food and Drug
Administration, 2009). The key metrics used to assess a new method are the major discrepancy
(MD) rate (the proportion of cases where the reference method predicts the infection is sensi-
tive to an antibiotic but the new method predicts it is resistant) and the very major discrepancy
(VMD) rate (which is the proportion of cases the reference method predicts the infection is
resistant but the new method predicts it is sensitive). For a diagnostic test to be approved by
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the International Standards Organization, both the MD and VMD < 3%. As noted earlier, our
method very rarely produces an incorrect definitive classification, and hence if ’unknown’ re-
sults can be excluded, our method, based on the results in this paper, satisfies these criteria. For
example, if we take a ‘worst’ case and consider only n= 3 then the VMD and MD for the first
resistance criterion are 0.0 % & 1.6 %, respectively, whilst for the second resistance criterion
the VMD and MD are 0.4 % & 0.8%. In making this comparison, we are not claiming that this
method is sufficiently accurate for use in a clinical microbiology workflow for diagnosing an-
tibiotic resistant infections – clearly many more mutations and proteins need to be tested – but
rather, in combination with the sensitivity and specificity analysis, it does show that this method
has the potential to predict the effect of novel and rare mutations on the action of antibiotics.
That the very major discrepancy rate is generally low but the proportion of classifications
that are returned with an ‘unknown’ phenotype falls as n, the number of free energy calculations
used to make a prediction, increases, suggests that a sensible way of applying this method would
be to initially run a small number of free energy calculations (say n= 5) and try classifying the
effect of the mutation. If a definitive result is returned, our analysis suggests that it is probably
correct and will not be altered by adding more data. Alternatively, if the method cannot classify
the effect of the mutation, then one can run additional free energy calculations until a definitive
’resistant’ or ’no effect’ classification can be made. In this way, some mutations would be
classified very quickly, and others, like F123L or L41F, would take longer, as one would expect
given the larger number of atoms being perturbed by the protein mutation.
Our approach has several weaknesses. Firstly, it assumes we know at a molecular level how
an antibiotic works, specifically that it is a competitive inhibitor of an essential gene and it is
mutations in that gene that we wish to examine; this is often, but not always, true. Secondly,
it requires a high resolution experimental structure of the relevant bacterial protein with the
antibiotic bound. Although the structural coverage of many bacterial genomes has more than
doubled in the last ten years, with some species now having the structures of over half their
proteins determined (Khafizov et al., 2014), the structural coverage of many pathogenic species
remains low. In common with all applications of classical molecular dynamics, we are making
two further key assumptions; (i) that our description of the molecular interactions is sufficiently
accurate and (ii) that we have adequately sampled the phase space of the molecules. The first
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is mitigated somewhat since it is protein atoms that are perturbed in the alchemical free energy
calculation, and the protein forcefield has been extensively optimised (unlike in drug discovery
where the atoms of a ligand, which inevitably are less well described, are perturbed). The sec-
ond is mitigated by repeating calculations and allowing neighbouring simulations to exchange
their Hamiltonians according to a Metropolis criterion. It is also difficult to calculate the relative
free binding energy for some mutations using alchemical free energy methods; those perturbing
large numbers of atoms are, as we have seen for e.g. F123L, take longer to converge. Finally,
unlike in drug discovery where binding free energies (or equivalently dissociation equilibrium
constants) are reported and to which one can directly compare predicted values of DDG, there is
a paucity of binding free energy measurements for antibiotics. Instead the discipline of clinical
microbiology measures and reports MIC values. It is possible, as we have done here, to relate
the MIC to how the binding free energy changes upon the introduction of the mutation, but this
requires several assumptions and is necessarily less direct.
Throughout this study we have calculated each component free energy (Equation S10 &
Fig. S7) using the same number of l simulations for the same duration, regardless of what type
of free energy is being calculated and the size of the mutation being studied. This is almost cer-
tainly highly inefficient; in future work we will examine how to optimise our approach so that
the minimum amount of computational resource is required to produce an accurate classification
in the shortest time possible. This will include determining if a large number of relatively short
simulations (as done here) is more accurate, at least when it comes to classifying, than a smaller
number of longer simulations. Although some progress has been made in recent years examin-
ing this question in the context of endpoint free energy methods (Coveney and Wan, 2016), it
has not yet been addressed for alchemical free energy calculations in general. Finally, it is only
through the successful application of our approach to other proteins in other clinically-important
pathogens where resistance is increasingly a problem, that it will be possible to determine if our
method, or another one like it also based on the chemistry and structure of proteins, could, one
day, be integrated into a genetics-based clinical microbiology pipeline.
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Significance
The discovery of antibiotics was one of humanity’s greatest achievements in the twentieth cen-
tury; however, the evolution of antibiotic resistance by pathogens now threatens many advances
of modern medicine. There is an urgent need for improved diagnostic tools so that resistant
infections can be identified and treated appropriately. Analysis of whole-genome sequence data
generated on affordable high-throughput platforms has the potential to allow resistant infec-
tions to be more rapidly and cheaply diagnosed in the clinic than conventional culture based
approaches. A key limitation of this approach is that it cannot identify whether rare or previ-
ously unseen mutations will be associated with drug susceptibility or resistance. Since many
antibiotics are competitive inhibitors, we hypothesise that mutations that confer resistance re-
duce how well the drug binds the target protein, whilst not significantly altering the binding free
energy of the natural substrate. In this case, predicting whether a mutation confers resistance
is equivalent to calculating the effect of the mutation on the binding free energies of both the
antibiotic and the natural substrate. By relating these quantities to the standard clinical microbi-
ology metric, the minimum inhibitory concentration (MIC), we are able to derive two different
clinically-based criteria for classifying the effect of mutations and show that alchemical free en-
ergy methods, a well-established class of methods from computational chemistry, can not only
predict which mutations confer resistance to trimethoprim, but are also quantitatively accurate.
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STAR METHODS
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the
corresponding author Philip Fowler
EXPERIMENTAL MODEL AND SUBJECT DETAILS
The clinical isolates tested in this study were collected and sequenced as described previously
(Gordon et al., 2014).
METHOD DETAILS
Trimethoprim Susceptibility Testing
Susceptibility of test isolates to trimethoprim was determined by E-test (bioMérieux, Marcy
l’Etoile, France) in accordance with the manufacturer’s instructions. Breakpoints were inter-
preted according to EUCAST guidelines (EUCAST, 2016).
System building and equilibration
An experimental structure of S. aureus DHFR with trimethoprim (TMP) and NADPH bound
(PDB:3FRE) was used to setup all simulations (Oefner et al., 2009). Apo structures were
created by removing TMP. The generalized AMBER forcefield in conjunction with AMBER
ff99SB-ILDN (Lindorff-Larsen et al., 2010) was used throughout and all simulations were car-
ried out using GROMACS 5.0.x (Abraham et al., 2015). The mutations in the protein were
represented using a dual topology and all GROMACS free energy topology files were prepared
using pmx (Gapsys et al., 2015b). Each protein was solvated by adding waters and ions resulting
in a simulation unit cell of dimensions 7.1 ⇥ 6.4 ⇥ 6.0 nm containing 27,077–27,120 atoms.
For each mutant, separate apo, TMP- and DHA-bound short equilibration simulations were run.
First the energy of each system was minimised using the steepest descent algorithm for 1000
steps, then the dynamics of the system evolved for 2.5 ns with an integration timestep of 1 fs.
Electrostatic forces were calculated using the particle mesh Ewald method with a real space
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cutoff of 1.2 nm. Van der Waals interactions were cutoff at 1.2 nm, with a switching function
applied from 0.9 nm. A Langevin thermostat with a time constant of 2 ps was applied to keep the
temperature at 310 K. The pressure was maintained at 1 atm by an isotropic Parinello-Rahman
barostat with a time constant of 1 ps and a compressibility of 4.46⇥ 10 5 bar 1. The lengths
of all bonds involving a hydrogen were constrained using the LINCS algorithm. Since all the
above simulations were run with l = 0 (i.e. wildtype sidechain), we then ran a short simula-
tion to ‘phase-in’ the mutant sidechain using the Alchembed procedure (Jefferys et al., 2015).
This was repeated for different snapshots taken during the 2.5 ns equilibration trajectory and
ensured that we had a range of starting conformations suitable for all the different alchemical
and end-point simulations.
Alchemical simulations and calculations
A thermodynamic cycle was constructed (Fig. S7) and changes in the free energy of binding
upon introduction of the mutation, DDG, was defined by a series of alchemical transformation
free energies. We followed best practice and, when changing one sidechain into another, cal-
culated three separate free energies (Klimovich et al., 2015). This was repeated first for the
apo protein (DG1) and then the complex (DG6). First the electrical charges on the perturbing
atoms are removed (DG11 & DG61), before the van der Waals terms on the disappearing and
appearing atoms are decoupled and coupled to the system, respectively (DG12 & DG62), using
a soft-core potential (Beutler et al., 1994; Zacharias et al., 1994). Finally the electrical charges
on the new atoms are switched on (DG13 & DG63). To keep the ligand within the active site,
the distance between the protein and ligand centres of mass were restrained using a harmonic
potential with a spring constant of 2000 kJ nm 1 mol 2. The reference distances for TMP and
DHA were 0.644 nm and 0.794 nm, respectively. The free energies of removing both restraints
were calculated (DG5 & DG7). The final free energy is derived in the Supplemental Information
and is given by
DDG= DG5+(DG61+DG62+DG63)  (DG11+DG12+DG13) DG7. (1)
Each free energy was calculated by running either 8, 11 or 16 simulations at equally-spaced
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values of the progress parameter, l , between 0 and 1. To accelerate convergence, each set of 8,
11 or 16 simulations were coupled and attempted to exchange Hamiltonians every 1,000 steps
(Sugita et al., 2000; Woods et al., 2003). Each set was run for 0.25 ns, meaning each free energy
calculation required between 26 and 52 ns of molecular dynamics simulation. Thirty two pairs
of (DDGTMP,DDGDHA) were calculated for each mutation (Table S3 and Fig. S5), 5 with 11⇥l
values, 5 with 16⇥l values and 22 with 8⇥l values. No correlation between the number of l
values and the magnitude of the resulting value of DDG was detected. Calculating 32 pairs of
DDG values for a single mutation therefore required 1.0 µs of molecular dynamics simulation.
Eight mutations were calculated in total (since the F99YL21V mutation was decomposed into
two separate mutations), making a total of 8.1 µs of molecular dynamics simulation. More
daunting is that this is composed of 32,344 separate molecular dynamics simulations. These
were stored and discovered using datreant, a flexible python module for handling heteroge-
neous file-based data (Dotson et al., 2016).
The first derivative of the internal energy at the specified value of l , as well as the internal
energy evaluated at all other values of l were written to disc every 0.1 ps. This permitted the
free energy (DG) to be calculated using either the multi-state Bennett acceptance ratio estimator
(MBAR) (Shirts and Chodera, 2008) by the alchemical-analysis python module (Klimovich
et al., 2015), or simple thermodynamic integration. Since no significant differences in DDG
values were observed, with the mean unsigned error in a value of DDG being between 0.1-0.3
kcal/mol, depending on the number of atoms being perturbed, the latter was used for simplicity.
A subset of the GROMACS input files is available for download allowing a single pair of DDG
values to be calculated for each mutant from https://github.com/philipwfowler/amr-free-energy-
dhfr-examples.
The simulation parameters are the same as for the equilibration simulations above, except
the tolerance factor for the Ewald sum is decreased to 10 6 to increase the accuracy of calculat-
ing electrostatic forces, as is standard in these types of calculations. To remove transient effects,
the first 20% of each simulation was discarded. Discarding more (50%) or less (10%) of the
data did not materially affect the results (Fig. S2).
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QUANTIFICATION AND STATISTICAL ANALYSIS
Throughout, standard errors were calculated at a confidence level of 95%, taking into account
the appropriate t-statistic for the sample size. This assumes each calculated value of DG is
independent, which is reasonable since they are started from different initial structures taken
from the equilibration simulations and run using different random seeds.
DATA AND SOFTWARE AVAILABILITY
The clinical isolates tested in this paper were sequenced in a previous study (Gordon et al., 2014)
and, as a result, can be found in the European Nucleotide Archive Sequence Read Archive under
study accession number ERP004655.
KEY RESOURCES TABLE
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Supplemental Information
Mutation Identifier TMP ETest MIC
F99Y C00003356 >32 mg/l
C00007077 >32 mg/l
C00007074 >32 mg/l
C00013181 >32 mg/l
C00000815 >32 mg/l
F99Y/L21V C00000825 >32 mg/l
L41F C00003323 32 mg/l
F123L C00001107 0.5 mg/l
C00003121 0.5 mg/l
C00013402 0.5 mg/l
A135T C00003374 0.38 mg/l
C00001194 0.75 mg/l
C00013217 0.5 mg/l
C00008638 1 mg/l
C00000857 0.38 mg/l
I83V C00012815 0.75 mg/l
C00008632 1 mg/l
C00001110 0.75 mg/l
C00001152 0.5 mg/l
C00003290 0.5 mg/l
V76A C00003280 0.38 mg/l
C00013201 1 mg/l
C00012748 1 mg/l
C00012825 1 mg/l
C00012751 1 mg/l
Table S1: Related to Figure 1. Clinical isolates used in this study and their trimethoprim minimum inhibitory concentrations
(MIC), as measured by bioMe´rieux E-test. The F99Y/L21V and L41F mutations were only observed once, and hence each
only has a single data point. Likewise the F123L mutation was only observed three times. For all other mutations five
randomly-selected clinical isolates were tested as described in the Methods.
Mutation mean MIC MIC range Phenotype DDDGTMP DHA
(mg/l) (95% confidence) (kcal/mol)
F99Y >32 – Resistant > 2.1
F99Y/L21V >32 – Resistant > 2.1
L41F 32 – Resistant 2.1
F123L 0.5 – Susceptible -0.5
A135T 0.6 0.3-0.9 Susceptible -0.4 ± 0.3
V76A 0.9 0.4-1.5 Susceptible -0.2 ± 0.4
I83V 0.7 0.5-1 Susceptible -0.3 ± 0.2
Table S2: Related to Figure 1. Mean and confidence intervals for the measured trimethoprim minimum inhibitory concentra-
tions (MIC), as measured by bioMe´rieux E-test, for the seven mutations chosen for this study. The mean MIC was calculated
using the geometric mean and 95% confidence intervals are estimated using the appropriate t-statistic. The resulting pheno-
types are consistent with the previously published study (Gordon et al., 2014).
Mutation PHE MIC values data (mg/l)
F99Y >32, >32
F99Y/L21V –
L41F –
F123L 0
A135T 0
V76A 0, 0, 0, 0, 1
I83V 0, 0, 1
Table S3: Related to Figure 1. The incidences and recorded trimethoprim minimum inhibitory concentrations (MIC) by
routine monitoring by Public Health England (PHE). Neither the F99Y/L21V or L41F mutation were observed. All isolates
containing any of the plasmid-encoded genes, dfrA, dfrG or dfrK, were excluded.
DDGTMP F99Y Y99L21V F99YL21V L21V L41F F123L A135T V76A I83V
01 1.88 1.31 3.20 2.44 3.81 0.27 -0.60 -1.60 0.52
02 1.47 2.53 4.00 1.77 1.52 1.11 -0.55 -0.45 -0.05
03 0.89 1.76 2.65 2.94 3.86 0.41 -0.03 -0.88 0.65
04 1.92 -0.28 1.63 0.94 0.80 2.17 0.02 -0.44 -0.15
05 1.82 1.03 2.85 2.78 4.29 -1.66 0.22 -1.36 1.68
06 1.46 2.43 3.89 2.05 5.62 0.51 0.04 -1.23 0.76
07 1.61 1.41 3.02 2.44 2.97 -0.28 0.48 -1.36 -0.26
08 0.64 0.80 1.44 3.52 2.60 1.07 0.04 -0.68 1.12
09 2.09 1.99 4.08 1.94 2.56 0.56 -0.96 -0.44 -0.38
10 1.91 0.21 2.12 1.87 4.05 0.76 -0.30 -0.52 0.41
11 0.57 1.48 2.05 1.67 0.77 -0.25 -0.21 -1.41 1.14
12 1.46 1.35 2.80 2.42 2.48 1.20 -0.35 -0.53 0.68
13 2.02 1.61 3.62 3.26 3.25 0.30 -0.35 -1.16 0.10
14 1.22 1.79 3.01 1.55 2.98 1.16 -0.59 -1.07 0.09
15 1.72 0.99 2.71 1.70 4.78 1.27 0.56 -1.48 0.24
16 0.64 1.71 2.35 2.62 2.87 0.58 0.15 0.24 0.36
17 0.46 2.47 2.93 1.46 1.99 -0.10 0.59 -0.35 0.46
18 1.63 1.18 2.81 2.02 1.40 -0.14 -0.92 -0.49 1.07
19 1.75 3.49 5.24 2.86 3.65 0.91 0.25 -0.71 1.49
20 1.03 2.63 3.66 1.77 3.63 1.30 -1.23 -1.34 0.70
21 1.56 1.60 3.16 2.20 5.29 0.39 -0.42 -0.74 0.76
22 1.26 3.30 4.56 2.06 2.56 -0.04 0.09 0.23 0.48
23 1.47 2.09 3.56 1.41 4.21 1.00 -0.41 -0.69 0.51
24 1.78 2.15 3.93 1.76 3.73 1.28 -0.71 -1.01 0.99
25 1.83 1.84 3.67 2.35 4.54 -0.09 0.71 -0.49 0.90
26 1.46 1.58 3.04 2.14 4.59 0.70 0.51 -0.90 1.13
27 1.55 1.97 3.52 1.76 5.47 0.45 -0.59 -1.27 0.75
28 1.36 0.77 2.12 2.45 4.26 0.60 -0.06 -1.05 0.50
29 1.64 2.06 3.69 1.89 5.85 1.04 0.15 -1.42 1.39
30 1.32 2.34 3.66 3.16 3.67 -1.40 0.04 -0.72 0.68
31 1.72 2.79 4.51 1.76 5.12 0.89 0.79 -0.86 0.53
32 1.72 2.44 4.16 2.16 4.49 0.38 -0.11 -1.26 1.05
1.46 1.78 3.24 2.16 3.55 0.51 -0.12 -0.86 0.63
n=32 ± ± ± ± ± ± ± ± ±
0.15 0.29 0.31 0.21 0.48 0.27 0.18 0.17 0.18
Table S4: Related to Figure 2. The values of DDGTMP for the seven DHFR mutations (kcal/mol). Thirty-two thermodynamic
integration calculations were run for each mutation. Each value is composed of eight separate free energies as per Equation 1
and the thermodynamic cycle (Fig. S5). The means and 95% confidence intervals are shown for both the first ten values and
all thirty-two. The confidence interval takes into account the relevant t-statistic for the sample size.
DDGDHA F99Y Y99L21V F99YL21V L21V L41F F123L A135T V76A I83V
01 -0.91 -2.39 -3.30 -2.27 2.15 -1.69 -0.11 -0.67 0.55
02 -1.07 -0.25 -1.32 -0.10 3.36 -0.06 -1.22 0.47 -0.01
03 -1.41 -1.76 -3.17 -1.02 0.35 0.15 0.36 -0.15 0.32
04 -1.03 -1.32 -2.34 -0.42 0.78 -0.12 -0.96 -0.01 -0.28
05 -1.07 -1.31 -2.38 0.02 1.44 0.62 0.74 -1.14 1.30
06 -0.17 -0.66 -0.82 1.88 2.53 0.53 -0.92 -1.32 0.73
07 -1.40 -0.73 -2.13 -0.45 2.37 -0.61 -0.05 -0.03 -0.03
08 -2.05 -1.44 -3.48 0.20 1.45 0.28 1.03 -0.74 1.45
09 -0.48 -0.68 -1.16 -0.56 1.52 0.25 -0.80 -0.28 0.28
10 -0.98 -1.05 -2.02 -0.78 1.91 0.55 -0.63 -0.11 0.23
11 -2.08 -1.08 -3.16 0.54 -1.97 -0.79 0.21 -0.98 0.24
12 -0.81 -1.56 -2.37 -0.68 2.28 -0.50 0.12 0.50 0.14
13 -0.76 1.49 0.73 0.26 0.34 -1.01 0.29 -0.90 0.61
14 -1.17 -0.77 -1.94 0.51 1.14 0.03 -0.45 -1.17 0.67
15 -0.53 -0.95 -1.48 -1.45 2.24 1.28 0.31 -1.19 0.06
16 -1.62 -0.04 -1.66 0.50 4.90 0.58 0.59 -0.59 0.17
17 -1.86 -0.58 -2.45 0.10 1.26 0.09 0.96 -0.32 0.92
18 -0.91 -2.36 -3.27 0.31 3.80 0.46 -0.86 -0.53 0.89
19 -0.58 1.66 1.09 0.81 0.04 -0.22 -0.08 -0.60 0.41
20 -0.92 -0.20 -1.12 -1.94 -0.13 0.89 -0.78 -0.55 1.24
21 -0.49 -0.33 -0.82 1.41 1.78 -2.66 -0.88 -0.71 -0.36
22 -0.97 1.53 0.56 -0.17 5.69 -0.23 -0.29 0.41 0.02
23 -0.92 -0.45 -1.37 0.00 0.92 0.14 -0.37 -0.70 0.18
24 0.11 -0.74 -0.63 -0.36 2.22 -1.00 0.18 -0.70 -0.09
25 -1.14 -0.30 -1.45 -1.61 2.52 -0.51 0.07 -1.21 0.67
26 -0.91 -0.92 -1.83 -2.63 0.92 -0.89 0.82 -0.89 0.82
27 -0.37 -0.07 -0.44 -0.26 2.35 1.17 0.17 -1.03 -0.25
28 -1.61 -0.75 -2.36 3.97 0.41 1.29 -0.38 -0.97 -0.36
29 -0.30 0.30 0.01 -5.13 4.64 -2.42 0.76 -0.70 0.95
30 -0.28 0.06 -0.21 -2.60 3.07 -2.29 -0.16 -0.90 0.81
31 -0.60 0.01 -0.59 -3.93 0.87 0.49 -0.64 -0.57 -0.47
32 -1.10 0.10 -1.00 -3.75 0.32 1.35 -0.08 -0.59 0.02
-0.95 -0.55 -1.50 -0.61 1.80 -0.15 -0.10 -0.59 0.37
n=32 ± ± ± ± ± ± ± ± ±
0.19 0.34 0.43 0.63 0.56 0.37 0.22 0.17 0.18
Table S5: Related to Figure 2. The values of DDGDHA for the seven DHFR mutations (kcal/mol). Thirty-two thermodynamic
integration calculations were run for each mutation. Each value is composed of eight separate free energies as per Equation 1
and the thermodynamic cycle (Fig. S5). The means and 95% confidence intervals are shown for both the first ten values and
all thirty-two. The confidence interval takes into account the relevant t-statistic for the sample size.
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Figure S1: Related to Figures 3 & 4. Discarding less (10% compared to 25%) data from the alchemical simulations does not
alter the classification of mutants. For a mutation to be classified as conferring resistance according either resistance criterion,
the predicted change in binding free energy must lie in the shaded area. All values here are the mean of 32 independent simu-
lations with 95% confidence limits calculated taking into account the appropriate t-statistic. Mutations are colored according
to the same scheme as Figure 1.
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Figure S2: Related to Figures 3 & 4. Discarding more (50% compared to 25%) data from the alchemical simulations does not
alter the classification of mutants. For a mutation to be classified as conferring resistance according either resistance criterion,
the predicted change in binding free energy must lie in the shaded area. All values here are the mean of 32 independent simu-
lations with 95% confidence limits calculated taking into account the appropriate t-statistic. Mutations are colored according
to the same scheme as Figure 1.
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Figure S3: Related to Figure 4. Increasing the number of independent calculations better resolves where a mutation lies in
the DDGDHA v. DDGTMP plane. As the number of calculations is increased from (A) n= 3, to (B) 5, (C) 10, (D) 16 and finally
(E) n = 32 the 95% confidence limits reduce which decreases the chance that a mutation is either incorrectly classified, or
classified as having an ‘unknown’ phenotype.
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Figure S4: Related to Figure 6. Increasing the number of independent calculations improves the classification by either
resistance criteria. (A) Using the first resistance criterion, if a small number of calculations (< 5) are run there is a small
chance of susceptible mutations being classified as resistant and a moderate chance of any mutation being classified as having
an unknown phenotype. As the number of calculations is increased past 10, these errors disappear and all mutations are either
correctly classified (as resistant or susceptible), or an unknown result is returned. The chance of an unknown phenotype being
returned falls steadily as the number of calculations increases, until at n = 32, we predict that five of the seven mutations,
would always be correctly classified and an ‘unknown’ result would be returned for F123L and I83L around half the time. (B)
The picture is similar if we apply the second resistance criterion, except that now it struggles to correctly classify the F123L
and L41F mutations. Again there is a small chance of a classification error when n < 5, which disappears as n increases.
The differences that arise from applying these two resistance criteria can be explained by considering where the mutations are
found on the DDGDHA v. DDGTMP plot (Fig. 4) in relation to the lines that define both resistance criteria. (C) We can improve
the performance slightly if we apply both resistance criteria, examine both results and allow any definitive classification
(‘resistant’ or ‘susceptible’) to overrule any ‘unknown’ classification.
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Figure S5: Related to the STAR Methods. (A) A simple kinetic scheme for the competitive inhibition of an enzyme, E, by
an inhibitor, I. The enzyme binds with a substrate, S, to produce an intermediate, ES, which then reacts yielding the product,
P, and the enzyme. Each step is labelled with forward and, where appropriate, reverse rate constants. (B) The Michaelis-
Menten constant is defined in terms of three rate constants. (C) The dissociation constants of the inhibitor, Ki, and substrate,
Ks. (D) The thermodynamic cycle used to calculate how the binding free energy of either trimethoprim or dihydrofolic acid
changes (DDG) when a mutation is introduced into S. aureus DHFR. In the alchemical transitions (i.e. when one amino acid
is transformed into another) we remove all the electrical charges on the atoms that are being perturbed, before vanishing and
appearing the atoms necessary to make the mutation before finally recharging the resulting atoms. A free energy is therefore
calculated separately for each step (e.g. DG11). A soft-core van der Waals potential is used throughout. To prevent the ligand
unbinding from the protein during the simulations, a restraining potential is applied. The free energy of removing this potential
is calculated for both the wild-type and mutant proteins. Hence, a total of eight alchemical free energy calculations are needed
for each value.
